

Advancements in the Field of Vaccines and Immunization

Stepano Calle *

Center for Vaccine Research, Regional Bio containment Laboratory, University of Pittsburgh, Pittsburgh, USA

EDITORIAL

“Vaccines and Immunization” is a global platform to discuss and learn Vaccines and Immunization, Vaccine Preventable Diseases, Plant-Based Vaccines, Types of Immunology, Immunoresearch & Immunotechnology, Autoimmune & Inflammatory Diseases, Immune Diseases, Making a Session Plan, Giving Vaccinations, HIV Vaccines, Vaccines Production and Development, Vaccines for Immune Mediated Diseases, Vaccine Safety & Efficacy.

Vaccines are antigenic substance prepared from the causative agent of a disease or a synthetic substitute, used to provide immunity against one or several diseases. Vaccine stimulates the immune system so that it can recognize the disease and protect from future infection.

On behalf of the Board of the Journal of Vaccines & Vaccination and my co-editors, I am glad to present the Volume 11, Issue 4 of the journal. The journal established in 2009 has now published 11 Volumes; six issues in a year. The journal is now getting indexed in Directory of Open Access Journals and also by different academic forums. All these are promising signs. We could reach this stage through the constant support of Board Members and intellectual generosity of the readers and contributors (authors and reviewers).

Journal of Vaccines & Vaccination is the most preferred and highly accessed Journal in the field of immunity to a particular disease and Vaccine. The Journal is indexed in PubMed, Scimago and Scholar among many other reputed scientific databases.

The journal covers a broad spectrum of topics for study that discusses theoretical and empirical aspects of Vaccines like Human Vaccine Trials, Veterinary Vaccines, Cancer Vaccines, Vaccine Adjuvants and hospital networks. The journal solicits manuscripts that discuss technical and medical advancements in Decision Science, Children Vaccines, HIV Vaccine Care Management, Vaccines, Quality and Access. Where we encourage authors to provide insight into their recently published journal.

At many instances members of the editorial board also prefer to submit their articles. Such practice is common in other reputed specialty Journals. In fact, Journal of Vaccines & Vaccination encourages editorial board members to actively contribute. However, no special privileges are given to anyone. All scientific manuscripts including editorials are subjected to peer review. Journal of Vaccines & Vaccination follows a double blind peer review process where identity of authors and reviewers is not revealed to each other. The review generally involves subject experts. The editorial team consisting of associate editors and assistant editors are involved in the entire article cycle starting from submission to final recommendation. The entire review process is carefully structured so as to minimize possibility of bias [1-9].

Journal of Vaccines & Vaccination functions on principles of scientific excellence, publication ethics and transparency. It makes mediatory that every article is submitted only through the online manuscript submission. These professional bodies have given guidelines related to publication ethics and conflict of interests.

The editorial team has followed guidelines to avoid any potential bias and conflict of interest. None of the reviewers had any conflict or competing interest. The date-wise records of all editorial steps are available in the journal system.

Finally, I would like to thank you, the contributors and readers for your interest in the journal and I encourage you to continue to send us your valuable feedback and ideas for further improvement of our journal.

REFERENCES

1. Choudhury SA, Matin F. Seroprevalence of Antibodies to Tetanus Toxoid and Diphtheria Toxoid in Perinatally Human Immunodeficiency Virus (HIV) - Infected Children and Adolescents. *J Vaccines Vaccin.*(2020); 11(3): 1-4.
2. Thabelo M, Azubuike BN The Burden of Disease from Congenital Rubella Syndrome in Lesotho, south africa. *J Vaccines Vaccin.* (2020); 11(3): 1-7.
3. Misra S. Integrat ive Approach Amid COVID -19 Crisis - A Perspective, Rajkot, India *J Vaccines Vaccin.* (2020); 11(3):1-7.

Corresponding author: Stepano Calle, Center for Vaccine Research, Regional Bio containment Laboratory, University of Pittsburgh, Pittsburgh, USA, Tel: 617-324-6693; E-mail: StepanCalle@webmail.co.za

Received date: July 5, 2020, **Accepted date:** July 20, 2020, **Published date:** July 27, 2020

Citation: Calle S (2020) Advancements in the Field of Vaccines and Immunization. *J Vaccines Vaccin.*11:e418. DOI: 10.35248/2157-7560.20.11.e418

Copyright: © 2020 Calle S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

4. Anirban D, Sonali S, Ahmed TMHM Understanding the Lacunae in Knowledge and Attitude Leading to Vaccine Hesitancy, India. *J Vaccines Vaccin.* (2020); 11(2):1-3.
5. Tazehkand MN, Hajipour O. Evaluating the Vaccine Potential of a Tetravalent Fusion Protein against Coronavirus. *J Vaccines Vaccin.* (2020) 11(2): 1-6.
6. Ezeome I, Ezugworie J. Male Acceptance of Human Papillomavirus Vaccine for Family Members in Enugu, South-East Nigeria. *J Vaccines Vaccin.* (2019); 10(6): 1-9.
7. Poteet E, Lewis P, Yu Z, Chen C, Yang G, Nehete PN, et al. SHIV Virus-like particles (VLPs) Vaccination Induces Partial Protection from SHIV Challenge in a Rhesus Macaque Model. *J Vaccines Vaccin.* (2019); 10(5) :1-13.
8. Petterson A, Haiwick G, Hermann J, Fergen B, Wakeland K, Chittack W, et al. (2019) *kJ* of Ingelvac PRRS® Modified Live Virus Vaccine against Heterologous Porcine Reproductive and Respiratory Syndrome Virus Challenges. *J Vaccines Vaccin* 10(4): 1-10.
9. Friedrich R, Patterson AR, Johnson W, Fergen B, Hernandez L, Liesner BG, et al. Efficacy of Porcine Circovirus Type 2a and 2d Based Vaccines Following PCV2 Challenge. *J Vaccines Vaccin .* (2018) 10:1-5.